Eterna Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
ERNA$2.05+9.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit | Description | Incorporated By Reference |
| 10.1 | Securities purchase agreement, dated as of September 24, 2024, between Eterna Therapeutics Inc. and the purchaser parties thereto | Exhibit 10.1 to Form 8k filed on September 25, 2024 |
| 10.2 | Form of pre-funded warrant issuable under the securities purchase agreement, dated as of September 24, 2024, between Eterna Therapeutics Inc. and the purchaser parties thereto | Exhibit 10.2 to Form 8k filed on October 29, 2024 |
| 10.3 | Form of exchange agreement, dated as of September 24, 2024, between Eterna Therapeutics Inc. and the parties thereto | Exhibit 10.3 to Form 8k filed on September 25, 2024 |
| 10.4 | Note purchase agreement, dated as of September 24, 2024, between Eterna Therapeutics Inc. and the purchaser parties thereto | Exhibit 10.4 to Form 8k filed on September 25, 2024 |
| 10.5 | Form of 12.0% senior convertible note issued under the note purchase agreement, dated as of September 24, 2024, between Eterna Therapeutics Inc. and the purchaser parties thereto | Exhibit 10.5 to Form 8k filed on September 24, 2024 |
| 10.6 | Form of pre-funded warrant issuable upon conversion of 12.0% senior convertible notes issued under the note purchase agreement, dated as of September 24, 2024, between Eterna Therapeutics Inc. and the purchaser parties thereto | Exhibit 10.3 to Form 8k filed on October 29, 2024 |
| 10.7 | Form of support agreement, dated as of September 24, 2024, between Eterna Therapeutics Inc. and the stockholder parties thereto | Exhibit 10.7 to Form 8k filed on September 24, 2024 |
| 10.8 | Form of lock-up agreement, dated as of September 24, 2024, between Eterna Therapeutics Inc. and the stockholder parties thereto | Exhibit 10.8 to Form 8k filed on September 24, 2024 |
| 10.9 | Registration Rights Agreement, dated October 29, 2024, between Eterna Therapeutics Inc. and the purchaser parties thereto | Exhibit 10.1 to Form 8-K Filed on October 29, 2024 |
| 10.10 | Exclusive License and Collaboration Agreement, effective as of September 9, 2024, with Factor Bioscience Limited | Filed herewith |
| 10.11 | Sublease Termination Agreement, dated August 9, 2024, between Eterna Therapeutics Inc. and E.R. Squibb & Sons, L.L.C. | Filed herewith |
| 31.1 | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Filed herewith |
| 31.2 | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Filed herewith |
| 32.1 | Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | Furnished herewith |
| 32.2 | Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | Furnished herewith |
| 101 | Inline XBRL Document Set for the financial statements and accompanying notes in Part I, Item 1, of this Quarterly Report on Form 10-Q. | Filed herewith |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.